banner add

Analysis of Alzheimer’s Drugs Stirs Debate About Their Effectiveness

The review said a certain class of drugs had little clinical benefit, but many Alzheimer’s experts criticized the analysis, saying it unfairly lumped failed drugs with two recently approved treatments.

from NYT > Health https://ift.tt/oNlPLsa
via IFTTT

No comments

Some Medicare Patients Can Now Get Free CBD

The Trump administration has authorized a test program to see if the cannabis compound can ease some symptoms and reduce health care costs a...

Theme images by PLAINVIEW. Powered by Blogger.